Published in Kidney Int on April 01, 1998
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol (2009) 5.91
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2006) 3.80
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet (2006) 3.24
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Ann Med (2006) 2.99
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet (2001) 2.92
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet (2001) 2.75
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med (2007) 2.55
Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics (2004) 2.43
Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet (1999) 2.42
Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet (2002) 2.29
Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol (2008) 2.19
Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med (2006) 2.07
Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2008) 1.99
Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet (2003) 1.92
Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol (2008) 1.89
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol (2010) 1.88
Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol (2008) 1.82
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol (2009) 1.70
Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol (2010) 1.68
aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol (2010) 1.67
Genetics and complement in atypical HUS. Pediatr Nephrol (2010) 1.64
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 1.59
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood (2007) 1.53
The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet (2009) 1.52
Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant (2012) 1.44
Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol (2005) 1.40
The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol (2017) 1.38
Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2013) 1.32
The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.31
Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol (2010) 1.28
Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem (2009) 1.21
Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.20
Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol (2005) 1.19
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem (2011) 1.15
Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2013) 1.14
Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol (2013) 1.14
Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2012) 1.14
Hemolytic uremic syndrome. Semin Immunopathol (2014) 1.12
Discrimination between host and pathogens by the complement system. Vaccine (2008) 1.11
Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) (2012) 1.10
Complement factor H and the hemolytic uremic syndrome. J Exp Med (2007) 1.10
Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr Purif (2010) 1.09
A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol (2009) 1.07
The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol (2003) 1.06
Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol (2011) 1.06
Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol (2005) 1.05
Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol (2007) 1.05
Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol (2014) 1.05
Glomerular diseases: genetic causes and future therapeutics. Nat Rev Nephrol (2010) 1.03
Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.03
A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.00
DGKE and atypical HUS. Nat Genet (2013) 0.98
New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep (2014) 0.96
A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS One (2014) 0.96
Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol (2004) 0.94
Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2014) 0.94
Kidney function, albuminuria and age-related macular degeneration in NHANES III. Nephrol Dial Transplant (2011) 0.93
Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol (2011) 0.92
What's new in haemolytic uraemic syndrome? Eur J Pediatr (2008) 0.91
Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol (2010) 0.89
Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. Drug Des Devel Ther (2013) 0.88
Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am J Kidney Dis (2008) 0.88
The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Mol Immunol (2015) 0.87
Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther (2012) 0.86
The kidney in thrombotic thrombocytopenic purpura. Minerva Med (2007) 0.85
HUS and TTP in Children. Pediatr Clin North Am (2013) 0.85
Pathogenesis and prognosis of thrombotic microangiopathy. Clin Exp Nephrol (2007) 0.84
Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatr Nephrol (2014) 0.83
Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr (2013) 0.83
Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol (2012) 0.83
The interaction between factor H and Von Willebrand factor. PLoS One (2013) 0.82
Management of hemolytic uremic syndrome. F1000Prime Rep (2014) 0.82
Atypical hemolytic-uremic syndrome: a case report and literature review. Am J Case Rep (2015) 0.81
Risk factors for poor renal prognosis in children with hemolytic uremic syndrome. Pediatr Nephrol (2003) 0.81
A novel method for direct measurement of complement convertases activity in human serum. Clin Exp Immunol (2014) 0.81
A case of atypical hemolytic uremic syndrome due to anti-factor H antibody in a patient presenting with a factor XII deficiency identified two novel mutations. Clin Exp Nephrol (2011) 0.80
Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol (2008) 0.80
Complement factor h gene abnormalities in haemolytic uraemic syndrome: from point mutations to hybrid gene. PLoS Med (2006) 0.80
Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report. J Med Case Rep (2015) 0.79
Complement factor H: using atomic resolution structure to illuminate disease mechanisms. Adv Exp Med Biol (2008) 0.79
Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol (2015) 0.79
Role of genetic polymorphisms in factor H and MBL genes in Tunisian patients with immunoglobulin A nephropathy. Int J Nephrol Renovasc Dis (2010) 0.78
Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatr Nephrol (2011) 0.78
Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exp Immunol (2015) 0.77
The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet (2016) 0.77
Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clin Exp Immunol (2009) 0.77
Complementopathies. Blood Rev (2017) 0.76
Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. Blood Transfus (2013) 0.76
A quantitative lateral flow assay to detect complement activation in blood. Anal Biochem (2015) 0.76
Atypical hemolytic uremic syndrome and mutation analysis of factor H gene in two Tunisian families. Int J Nephrol Renovasc Dis (2010) 0.76
Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol (2013) 0.76
Ten-year advances in immunopathology of glomerulonephritis: translated into patients' care or lost in translation? Semin Immunopathol (2014) 0.76
Prevalence in the General Population of a CFH Sequence Variant Associated with Atypical Haemolytic Uraemic Syndrome in an Extensive Family from Southwest England. Nephron Extra (2013) 0.75
Classical electrostatics in biology and chemistry. Science (1995) 17.26
Ankylosing spondylitis and HL-A 27. Lancet (1973) 11.99
Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet (1997) 6.85
Elective ventilation of potential organ donors. BMJ (1995) 5.50
Reiter's disease and HL-A 27. Lancet (1973) 4.10
Velo-cardio-facial syndrome associated with chromosome 22 deletions encompassing the DiGeorge locus. Lancet (1992) 4.07
Detection and characterisation of an overmodified type III collagen by analysis of non-cutaneous connective tissues in a patient with Ehlers-Danlos syndrome IV. J Med Genet (1992) 3.80
Reconciling the magnitude of the microscopic and macroscopic hydrophobic effects. Science (1991) 3.79
Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet (2001) 2.92
Acute anterior uveitis and HL-A 27. Lancet (1973) 2.74
X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol (2000) 2.71
Extracting hydrophobic free energies from experimental data: relationship to protein folding and theoretical models. Biochemistry (1991) 2.46
Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies. Lancet (1982) 2.30
Deletions within chromosome 22q11 in familial congenital heart disease. Lancet (1992) 2.29
Osteogenesis imperfecta: cloning of a pro-alpha 2(I) collagen gene with a frameshift mutation. J Biol Chem (1984) 2.25
An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23
A prospective cytogenetic study of 36 cases of DiGeorge syndrome. Am J Hum Genet (1992) 2.23
Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet (1994) 2.12
Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet (1990) 2.11
A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet (2000) 2.09
Loss-of-function mutations in the EGF-CFC gene CFC1 are associated with human left-right laterality defects. Nat Genet (2000) 1.92
Free-energy determinants of alpha-helix insertion into lipid bilayers. Biophys J (1996) 1.89
Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J (1973) 1.88
Automated ligand placement and refinement with a combined force field and shape potential. Acta Crystallogr D Biol Crystallogr (2006) 1.84
Genotypic and phenotypic spectrum in tricho-rhino-phalangeal syndrome types I and III. Am J Hum Genet (2000) 1.80
Centiles for adult head circumference. Arch Dis Child (1992) 1.71
HL-A 27 and arthropathies associated with ulcerative colitis and psoriasis. Lancet (1974) 1.68
Genetic linkage of the Muckle-Wells syndrome to chromosome 1q44. Am J Hum Genet (1999) 1.68
Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother (2008) 1.68
Identification of a mutation in synapsin I, a synaptic vesicle protein, in a family with epilepsy. J Med Genet (2004) 1.63
The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet (2005) 1.59
Delineation of two distinct 6p deletion syndromes. Hum Genet (1999) 1.59
Withdrawal of renal replacement therapy in Newcastle upon Tyne: 1964-1993. Nephrol Dial Transplant (1996) 1.56
The molecular defect in a nonlethal variant of osteogenesis imperfecta. Synthesis of pro-alpha 2(I) chains which are not incorporated into trimers of type I procollagen. J Biol Chem (1983) 1.52
Goodpasture's syndrome with normal renal function. Nephrol Dial Transplant (1996) 1.51
Safe preservation of human renal cadaver transplants by Euro-Collins solution up to 50 hours. Transplant Proc (1981) 1.50
DiGeorge syndrome with isolated aortic coarctation and isolated ventricular septal defect in three sibs with a 22q11 deletion of maternal origin. Br Heart J (1991) 1.46
Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics (1996) 1.46
No association between Alport's syndrome and antithyroid antibodies. Nephrol Dial Transplant (1992) 1.38
Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc (1987) 1.35
Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol (1996) 1.29
Nuclease S1 mapping of a homozygous mutation in the carboxyl-propeptide-coding region of the pro alpha 2(I) collagen gene in a patient with osteogenesis imperfecta. Proc Natl Acad Sci U S A (1984) 1.29
Ten guiding principles for teaching children and adolescents about medicines. US Pharmacopeia. Clin Ther (1999) 1.29
Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol (2000) 1.29
Organ donation. BMJ (1993) 1.27
Cystosarcoma phyllodes. A clinicopathologic study of 26 cases. Cancer (1986) 1.26
Ethics and elective ventilation. Br J Hosp Med (1994) 1.25
Effect of weight-loss on plasma and urinary levels of uric acid. Lancet (1972) 1.25
Visual search for a tilted target: tests of spatial uncertainty models. Q J Exp Psychol A (1998) 1.24
Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. Am J Hum Genet (2000) 1.24
Nutritional status of patients undergoing lung cancer operations. Ann Thorac Surg (2001) 1.24
Localized scleroderma and hemiatrophy in association with antibodies to double-stranded DNA. Postgrad Med J (1992) 1.23
Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet (2000) 1.23
The influence of nutritional status on complications after operations for lung cancer. Ann Thorac Surg (2001) 1.21
Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol (1997) 1.20
Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet (2002) 1.20
Primary, nonsyndromic vesicoureteric reflux and its nephropathy is genetically heterogeneous, with a locus on chromosome 1. Am J Hum Genet (2000) 1.18
Autosomal recessive Alport syndrome: immunohistochemical study of type IV collagen chain distribution. Kidney Int (1995) 1.16
Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int (1996) 1.15
Concanavalin A as a probe of phosphomannan molecular structure. Biochim Biophys Acta (1973) 1.14
Enhanced rectal potassium secretion in chronic renal insufficiency: evidence for large intestinal potassium adaptation in man. Clin Sci (Lond) (1986) 1.14
Autosomal recessive polycystic kidney disease in adulthood. Nephrol Dial Transplant (2001) 1.11
Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol (1993) 1.11
JAG1 mutations are found in approximately one third of patients presenting with only one or two clinical features of Alagille syndrome. Clin Genet (2011) 1.11
Clinical variability of osteogenesis imperfecta reflecting molecular heterogeneity: cysteine substitutions in the alpha 1(I) collagen chain producing lethal and mild forms. J Biol Chem (1986) 1.11
Maternal uniparental disomy for chromosome 2 in association with confined placental mosaicism for trisomy 2 and severe intrauterine growth retardation. Prenat Diagn (1996) 1.10
Continuous ambulatory peritoneal dialysis after the honeymoon: review of experience in Newcastle 1979-84. Br Med J (Clin Res Ed) (1986) 1.08
Four cases of amelia of the upper limb associated with anal atresia--is this VACTERL with extreme limb involvement? Clin Dysmorphol (1998) 1.07
Renal side effects of nonsteroidal antiinflammatory drugs: clinical relevance. Am J Kidney Dis (1986) 1.06
Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc (1996) 1.05
Viscosity of rice flour: a rheological and biological study. J Agric Food Chem (2003) 1.04
Genetics of hypercalciuric stone forming diseases. Kidney Int (2007) 1.04
Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans. Am J Physiol (1992) 1.03
The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation (1994) 1.03
Mutations in CHD7 in patients with CHARGE syndrome cause T-B + natural killer cell + severe combined immune deficiency and may cause Omenn-like syndrome. Clin Exp Immunol (2008) 1.02
Outcome of patients with tuberous sclerosis after renal transplantation. Transplantation (1990) 1.02
Long-term effect of hbs antigenemia on patient survival after renal transplantation. N Engl J Med (1977) 1.01
Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem (1998) 1.01
Staphylococcal septicaemia, endocarditis, and osteomyelitis in dialysis and renal transplant patients. Postgrad Med J (1980) 1.01
A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. J Biol Chem (2000) 1.01
Autosomal-dominant periodic fever with AA amyloidosis: Novel mutation in tumor necrosis factor receptor 1 gene Rapid Communication. Kidney Int (2001) 0.98
Ascertainment of myotonic dystrophy through cataract by selective screening. J Med Genet (1995) 0.97
The Gaussian Generalized Born model: application to small molecules. Phys Chem Chem Phys (2007) 0.97
FISH mapping of de novo apparently balanced chromosome rearrangements identifies characteristics associated with phenotypic abnormality. Am J Hum Genet (2008) 0.96
Multiple spontaneous ruptures of tendons in renal transplant recipient. Br Med J (Clin Res Ed) (1984) 0.96
Sequence and structure continuity of evolutionary importance improves protein functional site discovery and annotation. Protein Sci (2010) 0.96
Variability in clinical, genetic and protein abnormalities in manifesting carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord (1993) 0.95
Familial juvenile hyperuricemic nephropathy and autosomal dominant medullary cystic kidney disease type 2: two facets of the same disease? J Am Soc Nephrol (2001) 0.95
Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci (Lond) (1987) 0.95
Further mutations in Brain 4 (POU3F4) clarify the phenotype in the X-linked deafness, DFN3. Hum Mol Genet (1995) 0.95
Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int (1994) 0.94
Insulin-mediated changes in PD and glucose uptake after correction of acidosis in humans with CRF. Am J Physiol (1995) 0.94
Increase of physical activity level after successful renal transplantation: a 5 year follow-up study. Nephrol Dial Transplant (2001) 0.94
Course of Henoch-Schönlein nephritis after renal transplantation. Report on ten patients and review of the literature. Transplantation (1994) 0.94
Letter: Acute anterior uveitis and HL-A 27. Lancet (1974) 0.94
Perceived numerosity as a function of item size. Percept Mot Skills (1988) 0.93